Ro 3306
(Synonyms: 2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亚基]噻唑-4-酮) 目录号 : GC12348
Ro 3306是一种ATP竞争性抑制剂，主要靶向CDK1/cyclin B1（Ki值为35nmol/L）和CDK1/cyclin A复合物（Ki值为110nmol/L）。
Cas No.:872573-93-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ro 3306 functions as the ATP-competitive inhibitor targeting CDK1/cyclin B1 with Ki value of 35nmol/L, and targeting CDK1/cyclin A complexes with Ki value of 110nmol/L[1]. Ro 3306 has been widely used in cell cycle studies and anti-tumor assays[2].
In vitro, Ro 3306 exhibited an IC50 of 1.8μmol/L for WAC2 cell lines and the IC50 of 2.3μmol/L for NB69 cell lines after 48h treatment[3]. Ro 3306 treatment (5μmol/L, 24h) caused G2/M-phase cell cycle arrest and apoptosis in OCI-AML-3 cells, and reduced the levels of the antiapoptotic proteins Bcl-2 and survivin[4]. Ro 3306 treatment (10μmol/L, 20h) arrested immature porcine oocytes at the germinal vesicle (GV) stage[5].
In vivo, Ro 3306 treatment (Intraperitoneal injection) at a dose of 2mg/kg/day, every other day, for a week attenuated angiotensin II-mediated cardiac hypertrophy and cardiac fibrosis in male C57BL/6J mice[6]. Treatment with Ro 3306 at a dose of 1.5mg/kg/day for 5 days through intranasal administration inhibited infection with the influenza A PR/8 strain, prolonged the survival of infected mice, and significantly reduced viral load in BALB/c mice[7].
References:
[1] Vassilev L T, Tovar C, Chen S, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1[J]. Proceedings of the National Academy of Sciences, 2006, 103(28): 10660-10665.
[2] Sunada S, Saito H, Zhang D, et al. CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity[J]. Biochemical and biophysical research communications, 2021, 550: 56-61.
[3] Schwermer M, Lee S, Köster J, et al. Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors[J]. Oncotarget, 2015, 6(17): 15425.
[4] Kojima K, Shimanuki M, Shikami M, et al. Cyclin‐dependent kinase 1 inhibitor RO‐3306 enhances p53‐mediated Bax activation and mitochondrial apoptosis in AML[J]. Cancer science, 2009, 100(6): 1128-1136.
[5] Jang W I, Lin Z L, Lee S H, et al. A specific inhibitor of CDK1, RO-3306, reversibly arrests meiosis during in vitro maturation of porcine oocytes[J]. Animal reproduction science, 2014, 144(3-4): 102-108.
[6] Yamamoto T, Matsushima S, Okabe K, et al. Cyclin dependent kinase 1 (CDK1) positively regulates cardiac hypertrophy and fibrosis via TGF-beta pathway[J]. European Heart Journal, 2020, 41(Supplement_2): ehaa946. 3743.
[7] Zhao L, Yan Y, Dai Q, et al. The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection[J]. Antiviral Research, 2022, 201: 105296.
Ro 3306是一种ATP竞争性抑制剂，主要靶向CDK1/cyclin B1（Ki值为35nmol/L）和CDK1/cyclin A复合物（Ki值为110nmol/L）[1]。Ro 3306已被广泛应用于细胞周期研究和抗肿瘤实验[2]。
在体外，Ro 3306处理48小时后，对WAC2细胞系的IC50值为1.8μmol/L，对 NB69细胞系的IC50值为2.3μmol/L[3]。使用5μmol/L的Ro 3306处理24小时，可导致OCI-AML-3细胞在G2/M期发生细胞周期阻滞并诱导细胞凋亡，同时降低抗凋亡蛋白Bcl-2和survivin的表达水平[4]。10μmol/L的Ro 3306处理20小时可使未成熟猪卵母细胞停滞在生发泡（GV）期[5]。
在体内，腹腔注射Ro 3306（2mg/kg/day，隔日给药，持续一周）可显著减轻由血管紧张素II诱导的雄性C57BL/6J小鼠心肌肥大和心脏纤维化[6]。鼻内给药Ro 3306（1.5mg/kg/day，连续5天）能有效抑制甲型流感病毒PR/8株的感染，延长感染小鼠的存活时间，并显著降低 BALB/c小鼠肺部的病毒载量[7]。
| Cell experiment [1]: | |
Cell lines | OVCA-429 cells |
Preparation Method | OVCA-429 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) at 37 °C in an incubator with 5% CO2. The medium was supplemented with 2mmol/L L-glutamine, 100U/mL penicillin, and 100µg/mL streptomycin. OVCA-429 cells were seeded in 24-well plates at a density of 1×105cells. Each well was transfected with 100μmol/L si-Cdk1 and treated with Ro 3306 (0, 2.5, 5 and 10μmol/L) for 48h. Cells were fixed with 10% acetic acid solution containing 10% methanol, stained with 0.5% crystal violet for 1h, photographed and extracted with 1% SDS solution. The absorbance of the cell crystal violet extract at 595nm was measured using a microplate reader. For consistency, each experiment was performed at least three times. |
Reaction Conditions | 0, 2.5, 5 and 10μmol/L; 48h |
Applications | Ro 3306 significantly increased the proliferation of OVCA-429 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | KpB (K18-gT+/− 121; p53fl/fl; Brca1fl/fl) transgenic mice (KpB mice) |
Preparation Method | Breeding and maintenance Sixty mice of KpB were maintained on a 12h light/dark cycle with ad libitum access to food and water. Mimicking diet-induced obesity (DIO), one-half of the KpB female mice were fed an high-fat diet (HFD, 60% fat-derived calories), and the other one-half were fed a low-fat diet (LFD, fat-derived calories, Research Diets) at 3 weeks of age. All mice were injected with 5µL recombinant adenovirus Ad5-CMV-Cre (2.5×1010P.F.U) into the left ovarian bursa cavity at six to eight weeks old. The mice were maintained on HFD and LFD chow throughout the course of the treatment and were palpated every week to check for the presence of ovarian tumors. When palpable tumors had grown to a mean size of 0.1×0.1cm in diameter, the mice were randomly allocated to groups of four groups (HFD control, LFD control, HFD+Ro 3306, and LFD+Ro 3306, n=15 mice/group). When the ovarian tumor was about 0.1×0.1cm, KpB mice were injected with Ro 3306 (4mg/kg, i.p., every 3 days) for 4 weeks. Toxicity was evaluated daily according to clinically visible abnormalities and weight measurements were performed weekly during the treatment. Tumor development was followed by palpation twice a week until the tumor reached a size that could be measured with calipers. All mice were euthanized by CO2 asphyxiation following 4 weeks of treatment. Tumors and serum were obtained. Half of the tumor tissues were stored at −80°C, and the other tissue and serum were fixed in paraffin. Blood serum was collected and frozen at −80°C. The ovarian tumor volume was determined by the formula: (width2 × length)/2. |
Dosage form | 4mg/kg every 3 days for 4 weeks; i.p. |
Applications | Ro 3306 treatment significantly reduced tumor volume and tumor weight in KpB mice, and significantly inhibited Bcl-xL expression. |
References: | |
| Cas No. | 872573-93-8 | SDF | |
| 别名 | 2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亚基]噻唑-4-酮 | ||
| 化学名 | (Z)-5-(quinolin-6-ylmethylene)-2-((thiophen-2-ylmethyl)amino)thiazol-4(5H)-one | ||
| Canonical SMILES | O=C1N=C(NCC2=CC=CS2)S/C1=C\C3=CC=C(N=CC=C4)C4=C3 | ||
| 分子式 | C18H13N3OS2 | 分子量 | 351.45 |
| 溶解度 | ≥ 4.39mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8454 mL | 14.2268 mL | 28.4535 mL |
| 5 mM | 0.5691 mL | 2.8454 mL | 5.6907 mL |
| 10 mM | 0.2845 mL | 1.4227 mL | 2.8454 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet